Revenues up 10% over fiscal first quarter 2021, and 20% over fiscal fourth quarter 2021 Customer orders backlog of over $1.5 million at August 31, 2021 Following close of first fiscal quarter 2022, Walmart began online sales of Biomerica’s EZ… Read More
Financials
Biomerica Reports Fiscal 2021 Year End Results
Revenues increase 7.6% for fiscal 2021 vs fiscal 2020. InFoods IBS Endpoint Trial expected to be fully enrolled in less than 2 weeks. Biomerica receives multiple notices of allowance for patents covering the InFoods Technology Platform providing patent protection through… Read More
Biomerica Reports 208% Increase In Q3 Fiscal 2021 Sales, Over Q3 Fiscal 2020
Sales increase driven by first sales of COVID-19 Antigen Rapid Test in Europe after January 2021 CE Mark approval Awarded two new patents for InFoods diagnostic guided therapy technology, including the first Japanese patent InFoods IBS diagnostic-guided therapy clinical trial expecting top… Read More
Biomerica Reports Fiscal 2021 Second Quarter Financial Results and Provides Business Update
Biomerica expects completion of enrollment of its Irritable Bowel Syndrome Diagnostic-Guided Therapy clinical trial by end of April, 2021 FDA actively reviewing Company’s EUA submission for its first of its kind “at-home” Blood Collection kit used with the Biomerica COVID-19… Read More
Biomerica Reports Fiscal 2021 1st Quarter Financial Results
Download PDF
Year End Results 2020 — September 1, 2020
Biomerica Reports Fiscal Year End May 31, 2020 Financial Results Please Click Here for Press Release Safe Harbor Statement